Study guide

4.1 Respiratory Distress Syndrome (RDS) & Surfactant Deficiency

NCC Low Risk Neonatal Nursing RNC-LRN

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview & Maternal-Fetal Risk Assessment

1.1 RNC-LRN Exam Structure, Eligibility & Test Blueprint 1.2 Maternal Health Conditions & Prenatal Risk Factors 1.3 Intrapartum Events & Fetal Surveillance Interpretation 1.4 Antepartum Fetal Surveillance, Labor Progression & Perinatal Screening

2 Chapter 2: Comprehensive Neonatal Assessment & Gestational Age

2.1 Physical Assessment & Normal Variations vs. Abnormalities 2.2 Gestational Age Assessment: New Ballard Score & Maturity Classification 2.3 Neurobehavioral Assessment & Primitive Reflexes

3 Chapter 3: Neonatal Diagnostic & Laboratory Evaluation

3.1 Neonatal Blood Gas Interpretation & Acid-Base Balance 3.2 Hematologic & Metabolic Laboratory Diagnostics 3.3 Newborn Screening & Diagnostic Imaging Modalities

4 Chapter 4: Neonatal Respiratory Pathophysiology & Management

4.1 Respiratory Distress Syndrome (RDS) & Surfactant Deficiency 4.2 Transient Tachypnea of the Newborn (TTN) 4.3 Meconium Aspiration Syndrome (MAS) & Air Leaks 4.4 Apnea of Prematurity (AOP) & Persistent Pulmonary Hypertension (PPHN) 4.5 Oxygenation Assessment & Non-Invasive Respiratory Support

5 Chapter 5: Neonatal Cardiovascular Conditions & Hemodynamics

5.1 Fetal-to-Neonatal Circulatory Transition & Innocent Murmurs 5.2 Patent Ductus Arteriosus (PDA) & Ductal-Dependent Cardiac Lesions 5.3 Congenital Heart Defects & CCHD Pulse Oximetry Screening

6 Chapter 6: Neurologic & Gastrointestinal/Genitourinary Disorders

6.1 Hypoxic-Ischemic Encephalopathy (HIE) & Therapeutic Hypothermia 6.2 Neonatal Seizures & Intraventricular Hemorrhage (IVH) 6.3 Gastrointestinal Pathologies & Necrotizing Enterocolitis (NEC) 6.4 Congenital GI/GU Anomalies & Renal Function

7 Chapter 7: Hematology, Hyperbilirubinemia, and Genetic/Endocrine Conditions

7.1 Neonatal Hyperbilirubinemia & Kernicterus Risk 7.2 Hemolytic Disease & Neonatal Hematologic Disorders 7.3 Inborn Errors of Metabolism & Endocrine Disorders 7.4 Infant of a Diabetic Mother (IDM) & Chromosomal Anomalies

8 Chapter 8: Resuscitation & Immediate Neonatal Stabilization

8.1 Neonatal Resuscitation Program (NRP) 9th Edition Core Algorithm 8.2 Advanced Resuscitation: Chest Compressions & Emergency Medications 8.3 Post-Resuscitation Stabilization & The S.T.A.B.L.E. Framework

9 Chapter 9: Nutrition, Feeding & Gastrointestinal Support

9.1 Maternal Breast Milk, Lactation Support & Donor Milk 9.2 Nutritional Fortification & Specialized Formula Selection 9.3 Enteral Feeding Methods, Trophic Feeds & Gavage Administration

10 Chapter 10: Thermoregulation, Fluids, Electrolytes & Glucose Management

10.1 Thermoregulation & Prevention of Cold Stress 10.2 Fluid Requirements & Electrolyte Management 10.3 Neonatal Hypoglycemia Assessment & Management Protocols

11 Chapter 11: Infection Control, Sepsis & Neonatal Pharmacology

11.1 Early-Onset vs. Late-Onset Sepsis & Maternal GBS Management 11.2 Infection Prevention, CLABSI Bundles & Antimicrobial Stewardship 11.3 Neonatal Pharmacology & High-Alert Medication Administration 11.4 Congenital & Perinatal Infections, Sexually Transmitted Infections and Immune Function 11.5 Vitamin K, Eye Prophylaxis, Immunization & Routine Neonatal Medications

12 Chapter 12: Neurodevelopmental Care, Family-Centered Care & Discharge Transition

12.1 Developmental Care, Stress Reduction & Non-Pharmacologic Pain Management 12.2 Neonatal Abstinence Syndrome (NAS/NOWS) & Eat, Sleep, Console (ESC) 12.3 Discharge Readiness, Car Seat Challenge & Safe Sleep Education 12.4 Psychosocial Support, Family Adaptation & Perinatal Grief 12.5 Home Care Technology, Developmental Follow-Up & Community Referral

13 Chapter 13: Professional Issues, Safety, Quality & Ethics in Neonatal Nursing

13.1 Patient Safety, Error Prevention & Quality Improvement 13.2 Bioethics, Legal Standards & Family Advocacy

14 Chapter 14: Musculoskeletal, Integumentary & Birth Injury Conditions

14.1 Musculoskeletal Anomalies & Neonatal Birth Injuries 14.2 Neonatal Skin: Barrier Physiology, Normal Variations & Common Lesions

4.1 Respiratory Distress Syndrome (RDS) & Surfactant Deficiency

Key Takeaways Explain This Topic AI

RDS is primarily caused by developmental surfactant deficiency in alveolar type II pneumocytes, resulting in high alveolar surface tension, end-expiratory atelectasis, severe V/Q mismatch, intrapulmonary shunting, and refractory hypoxemia.

According to the Law of Laplace (P = 2T / r), smaller alveoli require higher opening pressures and collapse into larger alveoli without surfactant, which dynamically reduces surface tension (T) as alveolar radius (r) decreases.

Clinical hallmarks develop within the first hours of life: tachypnea (RR > 60 bpm), expiratory grunting (active vocal cord adduction maintaining functional residual capacity), intercostal/subcostal retractions, nasal flaring, and cyanosis in room air.

Classic radiographic findings include a diffuse, uniform reticulogranular 'ground-glass' appearance, prominent air bronchograms, and lung hypoaeration (< 8 posterior ribs visible on inspiration).

First-line management prioritizes early non-invasive CPAP (5-7 cmH2O); exogenous surfactant replacement (poractant alfa 200 mg/kg or beractant 100 mg/kg) is administered via minimally invasive (LISA/MIST) or standard endotracheal techniques, followed by immediate weaning of pressures and FiO2 to prevent hyperoxia, ROP, and pulmonary air leaks.

Last updated: August 2026

4.1 Respiratory Distress Syndrome (RDS) & Surfactant Deficiency

Respiratory Distress Syndrome (RDS), historically referred to as hyaline membrane disease, is the single most common cause of respiratory failure and neonatal intensive care unit (NICU) admission in preterm infants. The fundamental defect is a developmental deficiency in the production and secretion of pulmonary surfactant by alveolar type II pneumocytes. Without adequate surfactant, high alveolar surface tension causes progressive end-expiratory atelectasis, loss of functional residual capacity (FRC), intrapulmonary right-to-left shunting, and life-threatening hypoxemia.

  • 1. Surfactant Biochemistry & Biophysics
  • Biochemical Composition of Pulmonary Surfactant

Pulmonary surfactant is a complex lipoprotein mixture synthesized, packaged into lamellar bodies, and secreted by alveolar type II pneumocytes starting around 24 to 28 weeks of gestation, reaching functional maturity near 35 to 36 weeks. Surfactant consists of approximately 90% lipids and 10% specialized proteins :

Phospholipids (~80–85% of total mass):

Dipalmitoylphosphatidylcholine (DPPC / Lecithin): Accounts for ~50–60% of all phospholipids. DPPC is the primary surface-tension-lowering molecule. Its two saturated 16-carbon palmitic acid chains pack tightly together at the air-liquid interface, forming an insoluble monolayer capable of reducing surface tension to nearly zero ( < 1 − 2 mN/m < 1-2\text{ mN/m} < 1 − 2 mN/m ) during expiration.

Phosphatidylglycerol (PG): Comprises ~8–12% of lipids. PG enhances the rapid lateral spreading of DPPC across the alveolar surface. Its appearance in amniotic fluid at ~35–36 weeks signals biochemical fetal lung maturity.

Other Lipids: Phosphatidylethanolamine, phosphatidylinositol (PI), and neutral lipids (cholesterol).

Surfactant-Associated Proteins (SP-A, SP-B, SP-C, SP-D):

Hydrophobic Proteins (SP-B and SP-C): Essential for biophysical function. SP-B (79 amino acids) and SP-C accelerate the adsorption and insertion of phospholipids into the monolayer film and facilitate tubular myelin lattice formation. Clinical Pearl: Congenital SP-B deficiency (autosomal recessive mutation) causes lethal neonatal respiratory failure in term infants unresponsive to exogenous surfactant.

Hydrophilic Collectins (SP-A and SP-D): Function primarily in innate host defense and pulmonary immunity. They bind and opsonize viral, bacterial, and fungal pathogens, regulate alveolar macrophage phagocytosis, and modulate inflammatory cytokine cascades.

The Biophysics of Alveolar Stability: The Law of Laplace

The physical behavior of alveoli is governed by the Law of Laplace for spherical structures: P = 2 T r P = \frac{2T}{r} P = r 2 T ​

Where:

P P P = Collapsing pressure (inward pressure required to prevent collapse, or opening pressure required to expand the sphere)

T T T = Surface tension at the liquid-air interface

r r r = Alveolar radius Without Surfactant (Constant Surface Tension T):

  • Alveolus A (r = 1) ───► P = 2(10)/1 = 20 cmH2O [HIGH Pressure ──► Collapses into B]
  • Alveolus B (r = 2) ───► P = 2(10)/2 = 10 cmH2O [LOWER Pressure ─► Overdistends]

With Surfactant (Dynamic Surface Tension T drops as r shrinks):

  • Alveolus A (r = 1, T = 2) ──► P = 2(2)/1 = 4 cmH2O [STABLE: Pressures equalize]
  • Alveolus B (r = 2, T = 4) ──► P = 2(4)/2 = 4 cmH2O [STABLE: No alveolar collapse]

In a surfactant-deficient lung, surface tension ( T T T ) remains constant and high throughout the respiratory cycle. Consequently, smaller alveoli (smaller r r r ) generate significantly higher collapsing pressures ( P P P ) than larger adjacent alveoli, forcing gas to empty from smaller alveoli into larger ones. This produces diffuse microatelectasis in small units and localized overdistension in larger units. Surfactant dynamically reduces surface tension in direct proportion to alveolar compression: as the alveolus shrinks during expiration, DPPC molecules compress tightly together, driving T T T close to zero and eliminating the collapsing pressure gradient, thereby preserving alveolar stability and FRC.

2. Pathophysiological Cascade of RDS

Surfactant deficiency initiates a self-propagating cycle of mechanical failure, ventilation-perfusion mismatch, tissue injury, and secondary pulmonary hypertension:

Loss of Functional Residual Capacity (FRC): Without surfactant, end-expiratory alveolar collapse occurs after every breath. The neonate must exert immense negative intrathoracic pressure (high work of breathing) to reopen collapsed alveoli with each inspiration, leading to diaphragmatic muscle fatigue.

Decreased Pulmonary Compliance: The lungs become stiff and non-compliant, requiring high transpulmonary opening pressures.

Ventilation-Perfusion ( V ˙ / Q ˙ \dot{V}/\dot{Q} V ˙ / Q ˙ ​ ) Mismatch & Intrapulmonary Shunt: Blood perfuses non-ventilated, collapsed alveoli, creating a massive true right-to-left intrapulmonary shunt that results in severe hypoxemia refractory to simple supplemental oxygen.

Hypoventilation & Mixed Acidosis: Progressive atelectasis leads to alveolar hypoventilation, hypercapnia, and respiratory acidosis. Concurrently, severe cellular hypoxia causes anaerobic metabolism, lactic acid accumulation, and metabolic acidosis.

Endothelial Damage & Hyaline Membrane Formation: High shear stress from repeated alveolar opening/collapse, combined with ischemic capillary leak, causes protein-rich plasma exudate and fibrin to pour into alveolar spaces. This exudate coagulates into eosinophilic hyaline membranes lining the respiratory bronchioles and alveolar ducts. Fibrin and serum proteins directly inactivate any remaining endogenous surfactant, accelerating lung destruction.

Loading diagram... Pathophysiological Cascade of Neonatal Respiratory Distress Syndrome

3. Risk Factors & Perinatal Influences

Neonatal RDS risk is strongly modulated by gestational age, maternal metabolic state, mode of delivery, and fetal hormonal milieu.

Key Risk Factors

Prematurity: The single greatest predictor. Incidence is > 80 − 90 % > 80-90\% > 80 − 90% at < 28 < 28 < 28 weeks, ∼ 50 − 60 % \sim 50-60\% ∼ 50 − 60% at 28 − 32 28-32 28 − 32 weeks, ∼ 15 − 20 % \sim 15-20\% ∼ 15 − 20% at 32 − 34 32-34 32 − 34 weeks, and < 5 % < 5\% < 5% at ≥ 37 \ge 37 ≥ 37 weeks.

Maternal Diabetes (Infant of a Diabetic Mother - IDM): Maternal hyperglycemia causes fetal hyperglycemia and compensatory fetal hyperinsulinemia. High fetal insulin levels directly inhibit the transcription of surfactant proteins (SP-A and SP-B) and block cortisol-mediated induction of choline phosphate cytidylyltransferase, delaying biochemical lung maturity by 1 to 2 weeks.

Cesarean Delivery without Preceding Labor: Labor induces an endogenous surge of fetal catecholamines (epinephrine) and glucocorticoids, which stimulates surfactant exocytosis from lamellar bodies and activates epithelial sodium channels (ENaC) to clear lung liquid. Elective C-section bypasses these hormonal cues.

Perinatal Asphyxia, Acidosis, and Hypothermia: Alveolar ischemia and cold stress suppress type II pneumocyte metabolism, impairing surfactant synthesis and depleting intracellular ATP stores.

Male Sex: Androgens delay surfactant production relative to estrogens, conferring a 1.5- to 2-fold higher risk in male preterm infants.

Multiple Gestations: Second-born twins carry higher risk due to intrapartum hypoxia and cord clamping dynamics.

Protective Perinatal Factors (Accelerated Lung Maturation)

Antenatal Corticosteroid Therapy: Maternal administration of Betamethasone ( 12 mg 12\text{ mg} 12 mg IM q24h × 2 \times 2 × 2 doses) or Dexamethasone ( 6 mg 6\text{ mg} 6 mg IM q12h × 4 \times 4 × 4 doses) between 24 0 24^0 2 4 0 and 33 6 33^6 3 3 6 weeks (and late preterm 34 0 − 36 6 34^0-36^6 3 4 0 − 3 6 6 weeks) significantly upregulates surfactant synthesis enzymes, decreases RDS incidence by ∼ 50 % \sim 50\% ∼ 50% , and reduces intraventricular hemorrhage (IVH) and neonatal mortality.

Chronic Intrauterine Stress: Maternal preeclampsia, chronic hypertension, placental insufficiency, and prolonged premature rupture of membranes (PPROM) trigger endogenous fetal cortisol release, accelerating structural and biochemical alveolar maturation.

4. Clinical Presentation & Physical Assessment

Signs of RDS typically appear immediately in the delivery room or evolve within the first 2 to 4 hours of life, progressively worsening over 48 to 72 hours before natural recovery begins:

Tachypnea: Respiratory rate > 60 breaths/min > 60\text{ breaths/min} > 60 breaths/min (often 80 − 100 bpm 80-100\text{ bpm} 80 − 100 bpm ) as the infant compensates for low tidal volume ( V t V_t V t ​ ) by increasing frequency to maintain minute ventilation.

Expiratory Grunting: A critical compensatory mechanism. The neonate partially closes the glottis during active expiration against vocal cords, generating positive end-expiratory pressure ( 3 − 5 cmH 2 O 3-5\text{ cmH}_2\text{O} 3 − 5 cmH 2 ​ O ) to stent open terminal airways and preserve FRC.

Nasal Flaring: Reflex dilation of the anterior nares on inspiration, reducing upper airway resistance by up to 30 − 40 % 30-40\% 30 − 40% .

Chest Wall Retractions: Intercostal, subcostal, and substernal retractions occur because the preterm infant's highly compliant, cartilaginous ribcage collapses inward when generating high negative intrathoracic pressures against stiff, non-compliant lungs.

Paradoxical / Seesaw Respirations: Inward collapse of the anterior chest wall accompanied by outward abdominal distension during inspiration.

Central Cyanosis: Dusky or bluish discoloration of mucous membranes, lips, and tongue in room air, reflecting severe arterial hypoxemia.

Auscultation: Bilateral diminished breath sounds with a harsh, tubular quality, accompanied by fine end-inspiratory crackles.

The Silverman-Anderson Retraction Score

The Silverman-Anderson score provides a standardized 0-to-10 metric for serial quantification of neonatal respiratory distress (higher score = more severe distress):

  • Assessment Parameter Score 0 Score 1 Score 2
  • Upper Chest Movement Synchronized chest/abdomen Lag on inspiration Seesaw / paradoxical breathing
  • Lower Chest Retractions None Just visible Marked / deep
  • Xiphoid Retractions None Just visible Marked / deep
  • Nares Flaring None Minimal Marked / wide
  • Expiratory Grunt None Audible with stethoscope Audible with naked ear

Interpretation: Score 0 = No respiratory distress; Score 1–3 = Mild distress; Score 4–6 = Moderate distress; Score 7–10 = Severe distress / impending respiratory failure.

  • 5. Diagnostic Evaluation: Imaging & Blood Gases
  • Chest Radiography (CXR)

Classic Triad:

Diffuse Reticulogranular Pattern: Uniform, bilateral, finely mottled "ground-glass" parenchymal appearance resulting from widespread microatelectatic alveolar clusters interspersed with aerated alveolar ducts.

Prominent Air Bronchograms: Dark, air-filled major tracheobronchial branches visualized in sharp relief against the surrounding dense, opacified, collapsed lung parenchyma.

Hypoaeration / Underinflation: Diminished lung volumes with < 8 < 8 < 8 posterior ribs visible above the diaphragm on inspiration (bell-shaped thorax).

Radiographic Staging: Stage I (fine mild granularity) → \rightarrow → Stage II (moderate granularity with air bronchograms) → \rightarrow → Stage III (dense confluent opacities with blurred cardiac and diaphragmatic borders) → \rightarrow → Stage IV (complete "white-out" with total absence of air aeration).

Arterial Blood Gas (ABG) Characteristics

Early Phase: Hypoxemia ( PaO 2 < 50 mmHg \text{PaO}_2 < 50\text{ mmHg} PaO 2 ​ < 50 mmHg on room air) with normal or mildly elevated PaCO 2 \text{PaCO}_2 PaCO 2 ​ ( 45 − 50 mmHg 45-50\text{ mmHg} 45 − 50 mmHg ).

Progressive Phase: Severe respiratory acidosis ( pH < 7.25 \text{pH} < 7.25 pH < 7.25 , PaCO 2 > 55 − 70 mmHg \text{PaCO}_2 > 55-70\text{ mmHg} PaCO 2 ​ > 55 − 70 mmHg ) and secondary lactic metabolic acidosis ( HCO 3 − < 18 mEq/L \text{HCO}_3^- < 18\text{ mEq/L} HCO 3 − ​ < 18 mEq/L , Base Deficit > − 6 mEq/L > -6\text{ mEq/L} > − 6 mEq/L ). In severe cases, intrapulmonary and intracardiac right-to-left shunts cause refractory hypoxemia.

  • 6. Comprehensive Clinical Management & Nursing Priorities
  • 1. Non-Invasive Respiratory Support (First-Line)

Early CPAP: Initiating Continuous Positive Airway Pressure ( 5 − 7 cmH 2 O 5-7\text{ cmH}_2\text{O} 5 − 7 cmH 2 ​ O ) via binasal prongs or nasal mask immediately in the delivery room or nursery recruits collapsed alveoli, establishes FRC, prevents alveolar collapse at end-expiration, and reduces the need for endotracheal intubation and mechanical ventilation.

Heated Humidified High-Flow Nasal Cannula (HFNC): Flows of 4 − 8 L/min 4-8\text{ L/min} 4 − 8 L/min provide dead-space washout and mild positive distending pressure in stable recovering infants.

2. Exogenous Surfactant Replacement Therapy

Surfactant is indicated when clinical RDS diagnosis is established and the infant fails non-invasive CPAP (typically defined as requiring FiO 2 > 0.30 \text{FiO}_2 > 0.30 FiO 2 ​ > 0.30 on CPAP ≥ 6 cmH 2 O \text{CPAP} \ge 6\text{ cmH}_2\text{O} CPAP ≥ 6 cmH 2 ​ O or exhibiting severe retractions/acidosis).

Surfactant Product Source Standard Initial Dose Key Clinical Characteristics

Poractant alfa (Curosurf) Porcine (minced pig lung) 200 mg/kg 200\text{ mg/kg} 200 mg/kg ( 2.5 mL/kg 2.5\text{ mL/kg} 2.5 mL/kg ); repeat doses 100 mg/kg 100\text{ mg/kg} 100 mg/kg Rapid onset of action ( < 5 − 10 min < 5-10\text{ min} < 5 − 10 min ); lower volume, highest initial phospholipid concentration

Beractant (Survanta) Bovine (minced cow lung) 100 mg/kg 100\text{ mg/kg} 100 mg/kg ( 4.0 mL/kg 4.0\text{ mL/kg} 4.0 mL/kg ) q6h (max 4 doses) Modified natural extract supplemented with DPPC, palmitic acid, and tripalmitin

Calfactant (Infasurf) Bovine (calf lung lavage) 105 mg/kg 105\text{ mg/kg} 105 mg/kg ( 3.0 mL/kg 3.0\text{ mL/kg} 3.0 mL/kg ) q12h (max 3 doses) Lavage extraction preserving high native SP-B and SP-C ratios

Administration Modalities

LISA / MIST (Less Invasive Surfactant Administration / Minimally Invasive Surfactant Therapy): While the infant breathes spontaneously on non-invasive CPAP, a thin vascular catheter (16–18G) or feeding tube is placed through the vocal cords via direct laryngoscopy or video laryngoscopy. Surfactant is slowly instilled over 1 to 3 minutes. This avoids positive pressure bag ventilation and endotracheal intubation, preserving natural spontaneous breathing mechanics.

INSURE Method: IN tubate → \rightarrow → SUR factant administration via endotracheal tube → \rightarrow → rapid E xtubation to CPAP within 10 to 60 minutes.

Critical Post-Surfactant Nursing Priorities & Safety Warnings

Rapid Compliance Surge: Exogenous surfactant dramatically increases alveolar compliance within minutes of instillation. If ventilator settings are not rapidly adjusted, the delivered tidal volumes and transpulmonary pressures will skyrocket.

Immediate Weaning Mandate: The nurse and team must immediately wean Peak Inspiratory Pressure (PIP), Tidal Volume ( V t V_t V t ​ ), and FiO 2 \text{FiO}_2 FiO 2 ​ to prevent alveolar rupture, pulmonary air leaks (pneumothorax, pulmonary interstitial emphysema [PIE]), and acute hyperoxia.

Hyperoxia & ROP Prevention: Excessive arterial oxygen tension ( PaO 2 > 80 − 100 mmHg \text{PaO}_2 > 80-100\text{ mmHg} PaO 2 ​ > 80 − 100 mmHg ) damages immature retinal vasculature, causing vasoconstriction, endothelial necrosis, and subsequent Retinopathy of Prematurity (ROP) , as well as pulmonary oxygen toxicity (Bronchopulmonary Dysplasia [BPD]). Target pulse oximetry must be strictly maintained within safe ranges (preterm: 90 − 95 % 90-95\% 90 − 95% ).